Daily CSR
Daily CSR

Daily CSR

Daily news about corporate social responsibility, ethics and sustainability
Tags (2) : NMPA

AK0406: New Long-Acting Influenza Antiviral Approved in China

AK0406: New Long-Acting Influenza Antiviral Approved in China
08/18/2026 | Companies
Shanghai Ark Biopharmaceutical Co., Ltd announced today that China’s National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for AK0406 injection, the company’s first antiviral drug-Fc conjugate (AFC) candidate designed for long-acting influenza...
AFC, AK0406, antigenic drift, antiviral drug, antiviral drug-Fc conjugate, antiviral therapy, ArkBio, Australia, biopharmaceuticals, China, clinical development, drug development, global clinical development, HREC, IND approval, infectious diseases, influenza, influenza A, influenza B, influenza prevention, influenza prophylaxis, influenza vaccines, long-acting antiviral, NMPA, Phase I clinical trial, preclinical studies, prophylactic treatment, seasonal influenza, Shanghai Ark Biopharmaceutical, therapeutic treatment

Mabwell Advances 6MW5311 Bispecific Antibody for AML and Blood Cancers

Mabwell Advances 6MW5311 Bispecific Antibody for AML and Blood Cancers
04/16/2026 | Companies
Mabwell (688062.SH), an innovation-focused biopharmaceutical company with an integrated value chain, has announced that the National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for its novel LILRB4/CD3 T cell engager (TCE) bispecific antibody,...
6MW5311, acute myeloid leukemia, AML, biopharmaceuticals, biotechnology, bispecific antibody, cancer research, CD3, chronic myelomonocytic leukemia, clinical trials, CMML, cytotoxicity, drug development, FDA, hematologic malignancies, immune synapse, immunotherapy, IND application, LILRB4, Mabwell, MM, multiple myeloma, NMPA, oncology, preclinical studies, stem cell transplantation, steric hindrance, T cell engager, targeted therapy, TCE technology, tumor inhibition


Want to write a piece for Daily CSR? Please contact us by email at editor[@]dailycsr.com